Clinical Trials Logo
  1. Home
  2. Solid Tumors, Adult
  3. NCT06404528

Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours

Solid Tumors, Adult Clinical Trial

Official title:
A Clinical Study on the Efficacy and Mechanism of Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours

Clinical Trial Summary

By controlling the patient's blood sugar, small doses of chemotherapy are used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, and produce very strong anticancer effects without the cytotoxic effects of chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06404528
Study type Interventional
Source Wuxi People's Hospital
Contact Peihua Lu
Phone 0510-85350835
Email 13625653@qq.com
Status Recruiting
Phase N/A
Start date September 4, 2023
Completion date December 31, 2028
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04467853 - A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT05698888 - Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Phase 1
Recruiting NCT04587479 - A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT05472220 - Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Phase 1
Recruiting NCT05354323 - NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Phase 1
Recruiting NCT05430373 - GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors Phase 1
Recruiting NCT04739293 - Study of ON 123300 in Patients With Advanced Cancer Phase 1
Not yet recruiting NCT05747339 - A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors N/A
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05018273 - Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors Phase 1
Recruiting NCT04621435 - Imaging of Solid Tumors Using FAP-2286 Phase 1
Recruiting NCT05861895 - A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors Phase 1
Recruiting NCT06088472 - TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors Early Phase 1
Recruiting NCT05768139 - First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Phase 1/Phase 2